Liver‐specific deficiency of unc‐51 like kinase 1 and 2 protects mice from acetaminophen‐induced liver injury

Yu Sun, Terytty Yang Li, Lintao Song, Cixiong Zhang, Jingyi Li, Zhi‐Zhong Lin, Sheng‐Cai Lin, Shu‐Yong Lin – 22 December 2017 – unc‐51‐like autophagy activating kinase 1 and 2 (Ulk1/2) regulate autophagy initiation under various stress conditions. However, the physiological functions of these Ser/Thr kinases are not well characterized. Here, we show that mice with liver‐specific double knockout (LDKO) of Ulk1 and Ulk2 (Ulk1/2 LDKO) are viable, but exhibit overt hepatomegaly phenotype.

Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation

Zobair M. Younossi – 22 December 2017 – Nonalcoholic fatty liver disease (NAFLD), a common cause of chronic liver disease (CLD), has a global prevalence of 25%. Its progressive form, nonalcoholic steatohepatitis (NASH), is a leading indication for liver transplantation (LT) in the United States. As a result, specialty societies, including the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver, have developed guidance on the epidemiology, diagnosis, and treatment of NAFLD and NASH.

The case for normothermic machine perfusion in liver transplantation

Carlo D. L. Ceresa, David Nasralla, Constantin C. Coussios, Peter J. Friend – 22 December 2017 – In recent years, there has been growing interest in normothermic machine perfusion (NMP) as a preservation method in liver transplantation. In most countries, because of a donor organ shortage, an unacceptable number of patients die while awaiting transplantation. In an attempt to increase the number of donor organs available, transplant teams are implanting a greater number of high‐risk livers, including those from donation after circulatory death, older donors, and donors with steatosis.

Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation

Zobair M. Younossi – 22 December 2017 – Nonalcoholic fatty liver disease (NAFLD), a common cause of chronic liver disease (CLD), has a global prevalence of 25%. Its progressive form, nonalcoholic steatohepatitis (NASH), is a leading indication for liver transplantation (LT) in the United States. As a result, specialty societies, including the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver, have developed guidance on the epidemiology, diagnosis, and treatment of NAFLD and NASH.

Subscribe to